Close Menu

NEW YORK — Mesa Biotech said on Friday that it has received $13 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) for the development of a rapid point-of-care test for SARS-CoV-2 and influenza.

The visually read, PCR-based test will be designed to detect SARS-CoV-2 and influenza types A and B in throat, nasal, or nasopharyngeal swab samples within 30 minutes. It will run on Mesa's handheld Accula Dock system.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.